Talk:Trastuzumab emtansine
Jump to navigation
Jump to search
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||
| |||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Trastuzumab emtansine.
|
ado added to name
This Feb 2013 report adds ado- to the previous name to call it ado-trastuzumab emtansine. What is the significance of the ado- prefix ? - Rod57 (talk) 02:07, 23 February 2013 (UTC)
- According to the FDA review, to "mitigate against medication errors", i.e. to prevent Herceptin/Kadcyla mix-ups. This is not that unusual; atomoxetine, for instance, was initially named "tomoxetine"—the "a-" was added to prevent confusion with tamoxifen. Fvasconcellos (t·c) 02:57, 23 February 2013 (UTC)
Interesting that EMILIA showed no increase in 3 year survival
Figure 2. Second Interim Analysis of Overall Survival shows benefit at 12 and 24 months but not at 36 months. Not sure if that is unusual enough to mention in article. - Rod57 (talk) 11:11, 13 November 2015 (UTC)
- Its normal for the survival curves to converge at some point, as essentially all patients with metastatic cancer eventually die of their disease. Very few treatments are curative, and if you only delay death, convergence is inevitable.
- Also, at the 36 mo time point, the KM curve shows less than a dozen subjects at risk in each arm, so the data is a little noisy here.